JERSEY, Channel Islands , Feb. 14, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland , today announced that it has received the Conformité Européene (CE) Mark approval for the Initial Serological
Molecular Disease Screening Microarray Feasibility Study Completed Initial Serological Disease Screening FDA 510(k) Submission Accepted Commencement of EU Expanded Immunohematology Field Trial Activities Continued Strong Top Line Growth in the Quarter and Year to Date JERSEY, Channel Islands , Jan.
JERSEY, Channel Islands , Jan. 21, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ended December 31, 2019, will be released before market open on Thursday, January 30, 2020.
Initial Serological Disease Screening FDA 510k Submission Received Commencement of EU Extended Immunohematology Field Trial Activities JERSEY, Channel Islands , Jan. 10, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in
Chris Lindop to Remain as Executive Vice President Reporting to Franz Walt CEO JERSEY, Channel Islands , Jan. 07, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the planned appointment of Peter Buhler as Chief Financial
JERSEY, Channel Islands, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company’s Chief Executive Officer, Franz Walt , the Company’s President of R&D and Manufacturing, Ed Farrell , and the Company’s Chief
JERSEY, Channel Islands, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the closing of its previously announced underwritten public offering of 13,800,000 ordinary shares at a price to the public of $7.00 per
JERSEY, Channel Islands , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the pricing of its previously announced underwritten public offering of 12,000,000 ordinary shares at a price to the public of $7.00 per
JERSEY, Channel Islands, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the Company intends to commence an underwritten public offering of its ordinary shares. All of the ordinary shares to be sold in the
